Entity

Time filter

Source Type


Noussa-Yao J.,French Institute of Health and Medical Research | Noussa-Yao J.,University Pierre and Marie Curie | Boussadi A.,French Institute of Health and Medical Research | Richard M.,HOpital Europeen Georges Pompidou HEGP | And 2 more authors.
Studies in Health Technology and Informatics | Year: 2015

Purpose: Efficient and adequate coding is essential for all hospitals to optimize funding, follow activity, and perform epidemiological studies. Objective: We propose an autocompletion method for optimizing diagnostic coding in acute care hospitals. Methods: Using a terminology snowflake model integrating SNOMED 3.5 and ICD-10 codes, autocompletion algorithms generate a list of diagnostic expressions from partial input concepts. Results: A general autocompletion component has been developed and tested on a set of inpatient summary reports. Concepts expressed as strings of three or four characters return a noisy list of diagnostic labels or codes. Concepts expressed as groups of strings return lists that are semantically close to the labels present in hospital reports. The most pertinent information lies in the length of the expressions entered. Conclusion: Autocompletion can be a complementary tool to existing coding support systems. © 2015 European Federation for Medical Informatics (EFMI). Source


Petitguillaume A.,Institute for Radiological Protection and Nuclear Safety | Bernardini M.,HOpital Europeen Georges Pompidou HEGP | Hadid L.,Institute for Radiological Protection and Nuclear Safety | De Labriolle-Vaylet C.,University Pierre and Marie Curie | And 2 more authors.
Journal of Nuclear Medicine | Year: 2014

In the last decades, selective internal radiation therapy (SIRT) has become a real alternative in the treatment of unresectable hepatic cancers. In practice, the activity prescription is limited by the irradiation of organs at risk (OAR), such as the lungs and nontumoral liver (NTL). Its clinical implementation is therefore highly dependent on dosimetry. In that context, a 3-dimensional personalized dosimetry technique-personalized Monte Carlo dosimetry (PMCD)- based on patient-specific data and Monte Carlo calculations was developed and evaluated retrospectively on clinical data. Methods: The PMCD method was evaluated with data from technetium human albumin macroaggregates (99mTc-MAA) evaluations of 10 patients treated for hepatic metastases. Region-of-interest outlines were drawn on CT images to create patient-specific voxel phantoms using the OEDIPE software. Normalized 3-dimensional matrices of cumulated activity were generated from 99mTc-SPECT data. Absorbed doses at the voxel scale were then obtained with the MCNPX Monte Carlo code. The maximum-injectable activity (MIA) for tolerance criteria based on either OAR mean absorbed doses (D mean) or OAR dose-volume histograms (DVHs) was determined using OEDIPE. Those MIAs were compared with the one recommended by the partition model (PM) with Dmean tolerance criteria. Finally, OEDIPE was used to evaluate the absorbed doses delivered if those activities were injected to the patient and to generate the corresponding isodose curves and DVHs. Results: The MIA recommended using Dmean tolerance criteria is, in average, 27% higher with the PMCD method than with the PM. If tolerance criteria based on DVHs are used along with the PMCD, an increase of at least 40% of the MIA is conceivable, compared with the PM. For MIAs calculated with the PMCD, D mean delivered to tumoral liver (TL) ranged from 19.5 to 118 Gy for Dmean tolerance criteria whereas they ranged from 26.6 to 918 Gy with DVH tolerance criteria. Thus, using the PMCD method, which accounts for fixation heterogeneities, higher doses can be delivered to TL. Finally, absorbed doses to the lungs are not the limiting criterion for activity prescription. However, Dmean to the lungs can reach 15.0 Gy. Conclusion: Besides its feasibility and applicability in clinical routine, the interest for treatment optimization of a personalized Monte Carlo dosimetry in the context of SIRT was confirmed in this study. © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. Source


Le Blanche A.F.,University of Picardie Jules Verne | Le Blanche A.F.,Vascular Imaging | Ricco J.-B.,University of Poitiers | Bonneau M.,French National Institute for Agricultural Research | Reynaud P.,HOpital Europeen Georges Pompidou HEGP
CardioVascular and Interventional Radiology | Year: 2012

Purpose: Retrieval of optional caval filters may be impaired by filter tilting, migration, fracture, or embedding in the IVC wall. The goal of this experimental study was to evaluate a new optional filter, convertible by unlocking and removing the filter head. Methods: Forty-nine Pre-Alp sheep (average weight, 55 kg) were anesthetized. IVC was catheterized via the right femoral vein (n = 46) or via the internal jugular vein (n = 3) with a 12.9-F sheath. VenaTech™ Convertible™ IVC filters were inserted as either permanent filters (n = 14) or as filters to be converted. Conversion was immediately after deployment (n = 19) or delayed after 1, 3, or 6 months (n = 20). Filter delivery, deployment, and conversion with measurement of migration and tilting were evaluated by cavography. Incorporation of the filter's stabilizers and arms in the IVC wall was assessed by gross anatomy. Results: Delivery system insertion, filter release, and immediate conversion were successful in all cases. Delayed conversion was completed in all but one sheep, due to insufficient snare tension. Complimentary balloon-catheter inflation was required in 12 of 20 delayed conversions to achieve filter opening. In all 49 sheep, no thrombosis, migration, or significant tilting occurred. Within 4 weeks of conversion, the filter's stabilizers and arms were incorporated into the IVC wall. Upon removal, the filter head was free of intimal growth. Conclusions: The VenaTech ™ Convertible™ optional IVC filter was successfully implanted in all sheep with no migration or tilting. Conversion at various dates by filter head removal was feasible in all but one case. © 2011 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Source


Danchin N.,HOpital Europeen Georges Pompidou HEGP | Marzilli M.,Azienda Ospedaliero | Parkhomenko A.,Strazhesko Md Institute Of Cardiology | Ribeiro J.P.,Hospital de Clinicas de Porto Alegre | Ribeiro J.P.,Federal University of Rio Grande do Sul
Cardiology | Year: 2011

Aims: To compare the antianginal efficacy of trimetazidine with that of other agents with no influence on heart rate. Methods and Results: Medline and Embase databases were searched for blinded, randomized, controlled trials assessing the effects of non-heart-rate-lowering antianginal treatments on exercise tolerance and/or clinical criteria in stable angina patients. All relevant trimetazidine trials including the VASCO trial, the results of which are published herein, were included. A Bayesian network meta-analysis on the summary data was performed. Comparator antianginal agents were considered as a group and in agent/class subgroups. Trials involving β-blockers, non-dihydropyridine calcium channel blockers, and ivabradine were excluded. 218 trials totaling 19,028 patients were included in at least 1 network analysis. Effects of trimetazidine were statistically significant compared with placebo for exercise tolerance and clinical criteria. Transposition of results into seconds for clinical interpretation of exercise tolerance parameters showed a mean improvement of +46 s (95% credibility interval: 28; 66) for total exercise duration, +55 s (35; 77) for 1-mm ST segment depression (T1), and +54 s (24; 84) for time to onset of angina, in favor of trimetazidine. Differences between trimetazidine and active comparators were not significant when exercise tolerance and clinical criteria were analyzed, with +7 s (-12; 28) for total exercise duration, -1 s (-23; 22) for T1, +8 s (-22; 40) for time to onset of angina, and -0.28 (-1.17; 0.64) attacks per week for trimetazidine compared with antianginal agents as a group. Conclusions: Trimetazidine efficacy was comparable to that of other non-heart-rate-lowering antianginal treatments in patients with stable angina pectoris. Copyright © 2011 S. Karger AG, Basel. Source


Gey A.,HOpital Europeen Georges Pompidou HEGP | Tadie J.-M.,HOpital Europeen Georges Pompidou HEGP | Tadie J.-M.,University of Paris Descartes | Tadie J.-M.,Rennes University Hospital Center | And 16 more authors.
Clinical and Experimental Immunology | Year: 2015

Critically ill patients display a state of immunosuppression that has been attributed in part to decreased plasma arginine concentrations. However, we and other authors have failed to demonstrate a clinical benefit of L-arginine supplementation. We hypothesize that, in these critically ill patients, these low plasma arginine levels may be secondary to the presence of granulocytic myeloid-derived suppressor cells (gMDSC), which express arginase known to convert arginine into nitric oxide (NO) and citrulline. Indeed, in a series of 28 non-surgical critically ill patients, we showed a dramatic increase in gMDSC compared to healthy subjects (P=0·0002). A significant inverse correlation was observed between arginine levels and gMDSC (P=0·01). As expected, gMDSC expressed arginase preferentially in these patients. Patients with high gMDSC levels on admission to the medical intensive care unit (MICU) presented an increased risk of death at day 7 after admission (P=0·02). In contrast, neither plasma arginine levels, monocytic MDSC levels nor neutrophil levels were associated with overall survival at day 7. No relationship was found between body mass index (BMI) or simplified acute physiology score (SAPS) score, sequential organ failure assessment (SOFA) score or gMDSC levels, eliminating a possible bias concerning the direct prognostic role of these cells. As gMDSC exert their immunosuppressive activity via multiple mechanisms [production of prostaglandin E2 (PGE2), interleukin (IL)-10, arginase, etc.], it may be more relevant to target these cells, rather than simply supplementing with L-arginine to improve immunosuppression and its clinical consequences observed in critically ill patients. © 2014 British Society for Immunology. Source

Discover hidden collaborations